Alyeska Investment Group L.P. Has $4.58 Million Stake in Gossamer Bio, Inc. $GOSS

Key Points

• Alyeska Investment Group L.P. has reduced its stake in Gossamer Bio by 52.7%, selling 4,644,780 shares and now owning 4,163,734 shares valued at approximately $4.58 million.
• Despite the stake reduction, various institutional investors have been purchasing new stakes in Gossamer Bio, with a total of institutional ownership at 81.23%.
• Gossamer Bio has received mixed analyst ratings, with consensus indicating a "Buy" rating and an average target price of $8.50, despite recent downgrades from some analysts.

Alyeska Investment Group L.P. lowered its stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 52.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,163,734 shares of the company's stock after selling 4,644,780 shares during the quarter. Alyeska Investment Group L.P. owned approximately 1.83% of Gossamer Bio worth $4,580,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Graham Capital Management L.P. bought a new stake in Gossamer Bio in the fourth quarter valued at $32,000. Virtu Financial LLC acquired a new position in Gossamer Bio during the 1st quarter valued at about $38,000. Invesco Ltd. acquired a new position in Gossamer Bio during the 1st quarter valued at about $48,000. Fullcircle Wealth LLC bought a new position in Gossamer Bio in the 4th quarter worth about $43,000. Finally, Velan Capital Investment Management LP bought a new stake in shares of Gossamer Bio during the fourth quarter valued at approximately $68,000. 81.23% of the stock is owned by institutional investors and hedge funds.

Gossamer Bio Stock Up 11.7%

Shares of Gossamer Bio stock traded up $0.33 during trading on Wednesday, hitting $3.10. 9,542,033 shares of the stock traded hands, compared to its average volume of 2,160,521. The company has a fifty day moving average price of $1.96 and a two-hundred day moving average price of $1.42. Gossamer Bio, Inc. has a twelve month low of $0.66 and a twelve month high of $3.40. The stock has a market cap of $703.74 million, a P/E ratio of -4.99 and a beta of 1.95. The company has a debt-to-equity ratio of 6.70, a quick ratio of 4.40 and a current ratio of 4.40.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. Gossamer Bio had a negative net margin of 344.81% and a negative return on equity of 1,774.72%. The business had revenue of $11.49 million during the quarter, compared to analyst estimates of $4.12 million. Equities research analysts predict that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GOSS has been the subject of a number of recent analyst reports. Scotiabank started coverage on Gossamer Bio in a report on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 price objective for the company. Wall Street Zen lowered Gossamer Bio from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. The Goldman Sachs Group upped their price target on shares of Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Friday, May 16th. Finally, Wedbush boosted their price target on shares of Gossamer Bio from $4.00 to $5.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 6th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $8.50.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.